The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Malashenkova I.K.

National Research Center «Kurchatov Institute», Moscow

Hailov N.A.

National Research Center «Kurchatov Institute», Moscow

Krynskiy S.A.

National Research Center «Kurchatov Institute», Moscow

Ogurtsov D.P.

National Research Center «Kurchatov Institute»;
Federal and Clinical Center of PhysicalCchemical Medicine Russia

Kazanova G.V.

National Research Center «Kurchatov Institute», Moscow

Velichkovckiy B.B.

National Research Center «Kurchatov Institute», Moscow

Selezneva N.D.

Mental Health Research Centre

Fedorova Ya.B.

Mental Health Research Center

Ponomareva E.V.

Mental Health Research Center

Kolykhalov I.V.

Mental Health Research Center

Gavrilova S.I.

Mental Health Research Centre

Didkovsky N.A.

Research Institute of physical-chemical medicine, Moscow

Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis

Authors:

Malashenkova I.K., Hailov N.A., Krynskiy S.A., Ogurtsov D.P., Kazanova G.V., Velichkovckiy B.B., Selezneva N.D., Fedorova Ya.B., Ponomareva E.V., Kolykhalov I.V., Gavrilova S.I., Didkovsky N.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3): 39‑43

DOI: 10.17116/jnevro20161163139-43

Read: 1421 times

Download PDF (RU)
Contact the author
Table of contents

GLUTAMATE DEHYDROGENASE ACTIVITY IN PLATELETS OF PATIENTS WITH ENDOGENOUS PSYCHOSIS
GLUTAMATE DEHYDROGENASE ACTIVITY IN PLATELETS OF PATIENTS WITH ENDOGENOUS PSYCHOSIS

To cite this article:

Malashenkova IK, Hailov NA, Krynskiy SA, et al. Glutamate dehydrogenase activity in platelets of patients with endogenous psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3):39‑43. (In Russ.)
https://doi.org/10.17116/jnevro20161163139-43

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20
Features of facial expressions in patients with cognitive impairment due to Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):104-109
Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):133-139
The effe­cts of intraoperative use of angiogenesis inhi­bitors on outcomes and complication rates in the surgical treatment of proliferative diabetic reti­nopathy. Russian Annals of Ophthalmology. 2025;(2):44-50
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Abstract:

Objective — to evaluate the levels of cytokines (IFNα, IFNγ, IL-2, Il-4, IL-6, IL-8, IL-10, IL-12, IL-15), IL-1β receptor antagonist (IL-1RA), vascular endothelial growth factor (VEGF) and its antagonist, the soluble form of receptor 1 (sVEGFR1) in the blood serum of patients with Alzheimer’s disease, with early onset (ADEO) and late onset (ADLO), and in patients with mild cognitive impairment (MCI).

Material and methods. Levels of interleukins, IL-1RA, VEGF and sVEGFR1 were measured in 20 patients with AD and 11 patients with MCI using ELISA. These parameters were compared to the severity of cognitive impairment assessed by the performance on neurocognitive tests.

Results and conclusion. The levels of key cytokines (IL-8, TNFα, IL-12), VEGF and sVEGFR1 as well as anti-inflammatory proteins were different in patients with ADEO, ADLO and MCI. These differences suggest the phenotypic and genotypic heterogeneity of the disease that demands further research.

Keywords:

Alzheimer’s disease
mild cognitive impairment (MCI)
inflammatory and anti-inflammatory cytokines
IL-1 receptor antagonist (IL-1RA)
vascular endothelial growth factor (VEGF)
soluble receptor 1 of VEGF (sVEGFR1)

Authors:

Malashenkova I.K.

National Research Center «Kurchatov Institute», Moscow

Hailov N.A.

National Research Center «Kurchatov Institute», Moscow

Krynskiy S.A.

National Research Center «Kurchatov Institute», Moscow

Ogurtsov D.P.

National Research Center «Kurchatov Institute»;
Federal and Clinical Center of PhysicalCchemical Medicine Russia

Kazanova G.V.

National Research Center «Kurchatov Institute», Moscow

Velichkovckiy B.B.

National Research Center «Kurchatov Institute», Moscow

Selezneva N.D.

Mental Health Research Centre

Fedorova Ya.B.

Mental Health Research Center

Ponomareva E.V.

Mental Health Research Center

Kolykhalov I.V.

Mental Health Research Center

Gavrilova S.I.

Mental Health Research Centre

Didkovsky N.A.

Research Institute of physical-chemical medicine, Moscow

Close metadata

References:

  1. Jeffrey L Cummings, Bruce L et al. Creativity and Dementia: Emerging Diagnostic and Treatment Methods for Alzheimer’s Disease. Primary Psychiatry. 2008;15:2(suppl 1):1-24.
  2. Li X, Zhang ZJ. Neuropsychological and Neuroimaging Characteristics of Amnestic Mild Cognitive Impairment Subtypes: A Selective Overview. CNS Neurosci Ther. 2015. doi: 10.1111/cns.12391.
  3. Meraz-Ríos MA, Franco-Bocanegra D, Toral Rios D, Campos-Peña V. Early onset Alzheimer's disease and oxidative stress. Oxid Med Cell Longev. 2014;2014:375968. doi: 10.1155/2014/375968.
  4. Zou Z, Liu C, Che C, Huang H. Clinical genetics of Alzheimer's disease. Biomed Res Int. 2014;2014:291862. doi: 10.1155/2014/291862.
  5. Kljushnik TP, Androsova LV, Dupin AM. Vrozhdennyj immunitet i bolezn' Al'cgejmera. Psihiatrija. 2011;1:52-58. (In Russ.).
  6. Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014;50(2):534-544. doi: 10.1007/s12035-014-8657-1.
  7. Lueg G, Gross CC, Lohmann H. et al.Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging. 2015;36(1):81-89. doi: 10.1016/j.neurobiolaging.2014.08.008.
  8. Masera RG, Prolo P, Sartori ML et al. Mental deterioration correlates with response of natural killer (NK) cell activity to physiological modifiers in patients with short history of Alzheimer's disease. Psychoneuroendocrinology. 2002;27(4):447-461. doi: 10.1016/s0306-4530(01)00062-2.
  9. Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid â for Alzheimer's disease pathogenesis. J Neuroinflammation. 2014;11:48. doi: 10.1186/1742-2094-11-48.
  10. Kuhla A, Ludwig SC, Kuhla B et al. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain. Neurobiol Aging. 2015;36(2):753-761. doi: 10.1016/j.neurobiolaging.2014.09.025.
  11. Zilka N, Kazmerova Z, Jadhav S et al. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation. 2012;9:47. doi: 10.1186/1742-2094-9-47.
  12. Buerger S, Noack M, Kirazov LP et al. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci. 2009;27(6):517-523. doi: 10.1016/j.ijdevneu.2009.06.011.
  13. Hohman TJ, Bell SP, Jefferson AL. The Role of Vascular Endothelial Growth Factor in Neurodegeneration and Cognitive Decline: Exploring Interactions With Biomarkers of Alzheimer Disease. JAMA Neurol. 2015;72(5):520-529. doi: 10.1001/jamaneurol.2014.4761.
  14. Klettner A, Roider J. Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases. Graefes Arch Clin Exp Ophthalmol. 2009;247(11):1487-1492. doi: 10.1007/s00417-009-1139-x.
  15. Schafer G, Cramer T, Suske G et al. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem. 2003;278(10):8190-8198. doi: 10.1074/jbc.m211999200.
  16. Wu FT, Stefanini MO, Mac Gabhann F et al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14(3):528-552. doi: 10.1111/j.1582-4934.2009.00941.x.
  17. Yang SP, Kwon BO, Gho YS, Chae CB. Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity. J Neurochem. 2005;93(1):118-127. doi: 10.1111/j.1471-4159.2004.02993.x. 
  18. Motta M, Imbesi R, Di Rosa M et al. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett. 2007;114(1):46-51. doi: 10.1016/j.imlet.2007.09.002. 
  19. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer`s disease. Neurology. 1984;146:939-944. doi: 10.1212/wnl.34.7.939. 
  20. Petersen RC, Touchon J. Consensus on mild cognitive impairment. Research and Practice in Alzheimer’s Disease, E.A.D.C./A.D.C.S. Joint Meeting (Serdi Publisher, Paris). 2005;10:24-32.
  21. Alessenko AV, Bugrova AE, Dudnik LB. Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. Biochem Soc Trans. 2004;32(1):144-146. doi: 10.1042/bst0320144.
  22. Menachem-Zidon BO, Avital A, Ben-Menahem Y et al. Astrocytes support hippocampal-dependent memory and long-term potentiation via interleukin-1 signaling. Brain Behav Immun. 2011;25(5):1008-1016. doi: 10.1016/j.bbi.2010.11.007.
  23. Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med. 2015;3(10):136. doi:10.3978/ j.issn.2305-5839.2015.03.49.
  24. Belkhelfa M, Rafa H, Medjeber O et al. IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients. J Interferon Cytokine Res. 2014;34(11):839-847. doi: 10.1089/jir.2013.0085.
  25. Stoeck K, Schmitz M, Ebert E et al. Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis. J Neuroinflammation. 2014;11:170. doi: 10.1186/s12974-014-0170-y.
  26. Zhu XC, Tan L, Jiang T et al. Association of IL-12A and IL-12B polymorphisms with Alzheimer's disease susceptibility in a Han Chinese population. J Neuroimmunol. 2014;274(1-2):180-184. doi: 10.1016/j.jneuroim.2014.06.026.
  27. Malashenkova IK, Kazanova GV, Didkovskij NA. Interlejkin-15: stroenie, signaling i rol' v immunnoj zashhite. Molekuljarnaja medicina. 2014;3:9-20. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.